EA201792509A1 - Лечение рака - Google Patents

Лечение рака

Info

Publication number
EA201792509A1
EA201792509A1 EA201792509A EA201792509A EA201792509A1 EA 201792509 A1 EA201792509 A1 EA 201792509A1 EA 201792509 A EA201792509 A EA 201792509A EA 201792509 A EA201792509 A EA 201792509A EA 201792509 A1 EA201792509 A1 EA 201792509A1
Authority
EA
Eurasian Patent Office
Prior art keywords
cancer
nuc
stem cells
cancer stem
targeting
Prior art date
Application number
EA201792509A
Other languages
English (en)
Inventor
Хью Гриффит
Крис Макгиган
Крис Пеппер
Original Assignee
НУКАНА ПиЭлСи
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=53276184&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=EA201792509(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by НУКАНА ПиЭлСи filed Critical НУКАНА ПиЭлСи
Publication of EA201792509A1 publication Critical patent/EA201792509A1/ru

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
    • A61K31/7068—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/513—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim having oxo groups directly attached to the heterocyclic ring, e.g. cytosine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57484—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumor, cancer, neoplasia, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides, metabolites
    • G01N33/57496—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumor, cancer, neoplasia, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides, metabolites involving intracellular compounds
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6872—Intracellular protein regulatory factors and their receptors, e.g. including ion channels
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/52—Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Molecular Biology (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Cell Biology (AREA)
  • Immunology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Hematology (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Urology & Nephrology (AREA)
  • Biomedical Technology (AREA)
  • General Physics & Mathematics (AREA)
  • Biochemistry (AREA)
  • Pathology (AREA)
  • Biotechnology (AREA)
  • Food Science & Technology (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Microbiology (AREA)
  • Oncology (AREA)
  • Hospice & Palliative Care (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Investigating Or Analysing Biological Materials (AREA)

Abstract

Настоящее изобретение относится к NUC-1031 (гемцитабин[фенилбензокси-L-аланинил)]фосфату), то есть, к производному гемцитабина ProTide, для применения в нацеливании на раковые стволовые клетки. Такое нацеливание на раковые стволовые клетки может быть применено для профилактики или лечения рака. Настоящее изобретение также относится к NUC-1031 для применения в лечении рецидивирующего или не поддающегося лечению рака у человека. Не претендуя на какую-либо гипотезу, авторы лишь отмечают, что способность NUC-1031 нацеливаться на раковые стволовые клетки вносит свой вклад в его терапевтическую ценность в лечении рецидивирующего или не поддающегося лечению рака.
EA201792509A 2015-05-14 2015-05-14 Лечение рака EA201792509A1 (ru)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
PCT/GB2015/051438 WO2016181093A1 (en) 2015-05-14 2015-05-14 Cancer treatments

Publications (1)

Publication Number Publication Date
EA201792509A1 true EA201792509A1 (ru) 2018-05-31

Family

ID=53276184

Family Applications (1)

Application Number Title Priority Date Filing Date
EA201792509A EA201792509A1 (ru) 2015-05-14 2015-05-14 Лечение рака

Country Status (25)

Country Link
US (3) US20180289733A1 (ru)
EP (2) EP3415149A1 (ru)
JP (1) JP6761852B2 (ru)
KR (1) KR20180021697A (ru)
CN (2) CN115837028A (ru)
AU (2) AU2015394135B2 (ru)
BR (1) BR112017024461B1 (ru)
CA (1) CA2985540C (ru)
CY (1) CY1120516T1 (ru)
DK (1) DK3197456T3 (ru)
EA (1) EA201792509A1 (ru)
ES (1) ES2668377T3 (ru)
HR (1) HRP20180762T1 (ru)
HU (1) HUE038541T2 (ru)
IL (1) IL255591B (ru)
LT (1) LT3197456T (ru)
MX (2) MX2020009154A (ru)
MY (1) MY192081A (ru)
PH (1) PH12017502086A1 (ru)
PL (1) PL3197456T3 (ru)
PT (1) PT3197456T (ru)
RS (1) RS57371B1 (ru)
SI (1) SI3197456T1 (ru)
TR (1) TR201806642T4 (ru)
WO (1) WO2016181093A1 (ru)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0317009D0 (en) 2003-07-21 2003-08-27 Univ Cardiff Chemical compounds
RS62721B1 (sr) 2011-03-01 2022-01-31 NuCana plc Farmaceutska formulacija koja sadrži fosforamidatni derivat 5-fluoro-2’-deoksiuridina za upotrebu u lečenju kancera
RS56038B1 (sr) 2012-11-16 2017-09-29 Univ College Cardiff Consultants Ltd Smeša rp/sp gemcitabin-[fenil-(benziloksi-l-alaninil)]-fosfata
EA034890B1 (ru) 2014-06-25 2020-04-02 НУКАНА ПиЭлСи Продукты гемцитабина
MY186584A (en) 2014-06-25 2021-07-28 Nucana Biomed Ltd Formulation comprising a gemcitabine-prodrug
GB201417644D0 (en) 2014-10-06 2014-11-19 Nucana Biomed Ltd Method of separating phosphate diastereoisomers
EA031727B1 (ru) 2014-11-28 2019-02-28 Нукана Байомед Лимитед Новые производные 2'- и/или 5'-аминокислотных эфиров фосфороамидатов 3'-дезоксиаденозина в качестве противораковых соединений
JP6861702B2 (ja) 2015-09-25 2021-04-21 エフ．ホフマン−ラ ロシュ アーゲーＦ． Ｈｏｆｆｍａｎｎ−Ｌａ Ｒｏｃｈｅ Ａｋｔｉｅｎｇｅｓｅｌｌｓｃｈａｆｔ ソルターゼ・コンジュゲート化ループを含む組換え免疫グロブリン重鎖およびそのコンジュゲート
EP3359163B1 (en) 2015-10-05 2023-12-20 NuCana plc Combination therapy
PL3386998T3 (pl) 2015-12-11 2022-02-07 NuCana plc Diastereoselektywna synteza pochodnych fosforanu i proleku gemcytabiny nuc-1031
GB201522771D0 (en) 2015-12-23 2016-02-03 Nucana Biomed Ltd Crystalline form of a phosphate derivative
WO2017109444A1 (en) * 2015-12-23 2017-06-29 Nucana Biomed Limited Combination therapy
EA037459B1 (ru) * 2015-12-23 2021-03-30 НУКАНА ПиЭлСи Применение гемцитабин-[фенил-бензокси-l-аланинил]фосфата в комбинации с цисплатином для лечения рака мочевого пузыря или рака желчных путей
GB201609600D0 (en) * 2016-06-01 2016-07-13 Nucuna Biomed Ltd Cancer treatments
GB201709471D0 (en) 2017-06-14 2017-07-26 Nucana Biomed Ltd Diastereoselective synthesis of hosphate derivatives
GB201713916D0 (en) * 2017-08-30 2017-10-11 Nucana Biomed Ltd Treatment regimens
WO2020077353A2 (en) * 2018-10-12 2020-04-16 The Regents Of The University Of Colorado, A Body Corporate Compositions and methods for reducing cancer stem cells

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0317009D0 (en) 2003-07-21 2003-08-27 Univ Cardiff Chemical compounds
CA2736563C (en) 2007-09-10 2016-01-26 Boston Biomedical, Inc. A novel group of stat3 pathway inhibitors and cancer stem cell pathway inhibitors
CA2723648A1 (en) * 2008-04-10 2009-10-15 Piyush Gupta Methods for identification and use of agents targeting cancer stem cells

Also Published As

Publication number Publication date
WO2016181093A1 (en) 2016-11-17
CA2985540A1 (en) 2016-11-17
CY1120516T1 (el) 2019-07-10
HRP20180762T1 (hr) 2018-08-24
CN107835687A (zh) 2018-03-23
MY192081A (en) 2022-07-26
CA2985540C (en) 2021-08-24
US20210100825A1 (en) 2021-04-08
ES2668377T3 (es) 2018-05-17
MX2020009154A (es) 2022-03-08
MX2017014544A (es) 2018-09-26
BR112017024461A2 (pt) 2018-07-24
IL255591B (en) 2021-10-31
PL3197456T3 (pl) 2018-09-28
TR201806642T4 (tr) 2018-06-21
PT3197456T (pt) 2018-05-22
LT3197456T (lt) 2018-07-10
US20180289733A1 (en) 2018-10-11
DK3197456T3 (en) 2018-06-06
AU2015394135B2 (en) 2021-09-16
EP3197456B1 (en) 2018-04-04
HUE038541T2 (hu) 2018-10-29
EP3415149A1 (en) 2018-12-19
SI3197456T1 (en) 2018-08-31
AU2021277614A1 (en) 2021-12-23
EP3197456A1 (en) 2017-08-02
BR112017024461B1 (pt) 2023-04-04
EP3197456B2 (en) 2023-10-11
AU2015394135A1 (en) 2017-12-14
RS57371B1 (sr) 2018-08-31
US20230226092A1 (en) 2023-07-20
CN115837028A (zh) 2023-03-24
JP6761852B2 (ja) 2020-09-30
KR20180021697A (ko) 2018-03-05
IL255591A (en) 2018-01-31
JP2018515618A (ja) 2018-06-14
PH12017502086A1 (en) 2018-04-30

Similar Documents

Publication Publication Date Title
EA201792509A1 (ru) Лечение рака
BR112018007526A2 (pt) compostos de benzolactama como inibidores de proteína quinase
BR112017020895A2 (pt) inibidores de indolamina-2,3-dioxigenase para o tratamento de câncer
BR112018008326A2 (pt) composições e métodos para o tratamento de câncer
MX2021006734A (es) Metodo para tratar el cancer.
PH12017501483A1 (en) Bicyclic heterocycles as fgfr4 inhibitors
BR112018067368A2 (pt) terapia de combinação com anticorpos anti-cd73
EA201692511A1 (ru) Комбинированное лечение ингибиторами глутаминазы
BR112015026307A2 (pt) heterociclo bicíclicos como inibidores de fgfr
EA201890161A1 (ru) Терапевтические композиции, комбинации и способы применения
MX2018008346A (es) Terapia de combinación de virus oncológico e inhibidor de punto de control.
MX2017009571A (es) Inhibidores heterociclicos de itk para el tratamiento de la inflamacion y cancer.
EP3148336A4 (en) Use of eribulin and poly (adp ribose) polymerase (parp) inhibitors as combination therapy for the treatment of cancer
EP4252851A3 (en) Ezh2 inhibitors for treating lymphoma
BR112015032595A8 (pt) inibidores de ido
EA201892802A1 (ru) Производные аденозина для применения при лечении рака
MX2017013142A (es) Terapia combinada para tratar cáncer.
MX2018002344A (es) Metodo para tratar el cancer.
EA201891539A1 (ru) Соединения, ингибирующие металлоферменты
BR112015026297A2 (pt) terapia combinada composta por um inibidor tor quinase e um composto de 5-quinazolinona substituído para o tratamento de câncer
TR201901077T4 (tr) Kanser Veya Enfeksiyon Tedavisine Yönelik Birleşik Preparasyonlar
MX2016013600A (es) Método para tratar adenocarcinoma de pulmón.
BR112017009552A8 (pt) Métodos para alvejar o controle transcricional em regiões de super-realçador
MX2016009655A (es) Metodos novedosos para el tratamiento del cancer.
BR112017018198A2 (pt) inibição da atividade de olig2